Movantik

Active Ingredient(s): Naloxegol
FDA Approved: * September 16, 2014
Pharm Company: * ASTRAZENECA PHARMS
Category: Opioid Dependence

Naloxegol (INN; PEGylated naloxol;[1] trade names Movantik and Moventig) is a peripherally acting μ-opioid receptor antagonist developed by AstraZeneca, licensed from Nektar Therapeutics, for the treatment of opioid-induced constipation.[2] It was approved in 2014 in adult patients with chronic, non-cancer pain.[3] Doses of 25mg were found safe and well tolerated for 52 weeks.[4] When given concomitantly with opioid analgesi... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
11 Discussions